Skip to main content
. 2023 Oct 9;2023(4):hoad038. doi: 10.1093/hropen/hoad038

Table 1.

Baseline characteristics of healthy controls and the infertile patients recruited to study the prevalence of subclinical hypothyroidism, and of the previously infertile patients recruited for follow-up during pregnancy.

No. Age (y.) Age at menarche (y.) Duration of menstrual cycle (d.) BMI (kg/m2) RR systolic (mm Hg) RR diastolic (mm Hg) Heartbeat frequency (per min) Baseline TSH (mIU/l) Baseline anti-TPO (IU/l)
Prevalence study
Infertile patients 155 33.7 ± 0.7 13.3 ± 0.3 28.1 ± 0.9 23.0 ± 0.6 122.1 ± 2.1 72.0 ± 0.4 72.0 ± 1.6 1.94 ± 1.50 22.7 ± 8.5
Healthy controls 154 32.3 ± 0.9 13.0 ± 0.2 27.5 ± 0.4 23.2 ± 0.6 124.9 ± 1.9 73.4 ± 1.2 72.5 ± 1.6 1.73 ± 1.20 47.7 ± 18.0
ANOVA F(1, 306) = 5.7P = 0.018 F(1, 306) = 2.8 P = 0.094 F(1, 306) = 1.3 P = 0.252 F(1, 306) = 0.1 P = 0.722 F(1, 306) = 3.6 P = 0.058 F(1, 306) = 1.8 P = 0.182 F(1, 306) = 1.8 P = 0.182 F(1, 306) = 0 P = 0.840 F(1, 306) = 3.9P = 0.049
Pregnancy follow-up study
Group 1 17 33.4 ± 2.1 13.4 ± 0.7 30.6 ± 1.9 24.9 ± 2.2 123.3 ± 5.2 74.2 ± 3.7 73.5 ± 4.9 1.5 ± 0.2 10.1 ± 0.2
Group 2 14 32.9 ± 1.5 12.9 ± 0.9 33.9 ± 8.6 23.8 ± 1.9 124.6 ± 7.2 75.6 ± 5.2 75.2 ± 8.2 3.4 ± 0.3 11.3 ± 2.5
Group 3 17 32.8 ± 2.0 12.9 ± 0.9 28.5 ± 1.2 23.7 ± 2.5 117.8 ± 5.3 70.8 ± 3.6 72.7 ± 4.7 5.9 ± 0.6 13.3 ± 3.6
Group 4 9 31.0 ± 2.9 13.4 ± 1.2 35.2 ± 13.4 25.2 ± 4.7 123.7 ± 10.6 72.4 ± 5.7 74.9 ± 6.9 2.1 ± 0.4 264 ± 199
Group 5 12 33.0 ± 2.8 13.1 ± 1.0 30.0 ± 2.8 23.6 ± 1.9 124.3 ± 7.3 74.3 ± 5.5 72.9 ± 3.1 3.8 ± 0.6 429 ± 172
Group 6 16 33.9 ± 2.0 13.5 ± 0.8 29.4 ± 2.4 21.8 ± 1.6 118.9 ± 7.3 74.3 ± 5.1 73.9 ± 4.6 8.0 ± 2.1 1035 ± 506
ANOVA F(5, 79) = 0.6 P = 0.710 F(5, 79) = 0.4 P = 0.862 F(5, 79) = 0.9 P = 0.501 F(5, 79) = 0.2 P = 0.990 F(5, 79) = 0.8 P = 0.562 F(5, 79) = 0.5 P = 0.742 F(5, 79) = 0.1 P = 0.987 F(5, 79) = 22.5P < 0.00001 F(5, 79) = 11.4P < 0.00001

Group 1: TSH <2.5 mIU/l and anti-TPO <100 IU/ml.

Group 2: TSH >2.5–4.5 mIU/l and anti-TPO <100 IU/ml.

Group 3: TSH > 4.5 mIU/l and anti-TPO <100 IU/ml.

Group 4: TSH <2.5 mIU/l and anti-TPO >100 IU/ml.

Group 5: TSH >2.5–4.5 mIU/l and anti-TPO >100 IU/ml.

Group 6: TSH > 4.5 mIU/l and anti-TPO >100 IU/ml.

TSH, thyroid-stimulating hormone; anti-TPO, thyroid peroxidase antibodies; RR: risk ratio.